Grassley Planning to Investigate Orphan Designation’s Impact on High Drug Prices

Sen. Chuck Grassley (R-Iowa) is planning to examine the FDA’s orphan drug programs to find out if companies are using the designation to justify higher prices for common drugs.
Source: Drug Industry Daily